BI, Lilly To Study Jardiance As Heart Failure Therapy
This article was originally published in Scrip
Boehringer Ingelheim and Eli Lilly will launch two outcomes trials within the next 12 months investigating their jointly developed diabetes medicine Jardiance (empagliflozin) as a treatment for people with chronic heart failure – enrolling patients both with and without type 2 diabetes.
You may also be interested in...
With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.
Eli Lilly leads the way in diabetes and is using its current portfolio to find advantageous opportunities in related therapeutic areas.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.